Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.

There were no significant differences in the rates of non-SARS-CoV-2 infection, thrombotic events, or clinically significant bleeding, but allocation to baricitinib was associated with a nominally significant reduction in new onset cardiac arrythmia (2·3% vs 3·2%, p=0·017; appendix p 58 ).

also in 7,732 other papers